Actelion, Under Pressure To Diversify, Eyes Rare Disease Start-Up Ceptaris
This article was originally published in The Pink Sheet Daily
Executive Summary
Actelion is paying a $25 million upfront for an option to acquire Ceptaris Therapeutics, contingent upon the latter’s receiving FDA approval for its only asset, Valchlor, which faces an August PDUFA date. If the deal closes, Ceptaris will receive another $225 million plus milestones from the Swiss-based biotech.
You may also be interested in...
Tigercat Pharma Results From A Regional Partnership For CMEA's Velocity
The asset-focused operator of virtual biotechs teamed with Texas early-stage investment group Remeditex to back a new entity. Tigercat has filed an IND to investigate serlopitant for chronic itching.
Deals Of The Week: Busy ROR Gamma T Space Offers Small Molecule Promise In Autoimmune Disorders
Amgen’s July 31 deal with Japan’s Teijin marks at least the six partnerships around RORγt inhibitor compounds since 2009, with one more such deal likely this year. Plus news from a busy deal-making week, including tie-ups for AstraZeneca and Fibrogen, Actelion and Ceptaris, and Bristol and Samsung.
Actelion Braces For Tracleer Patent Cliff With New Drugs, New Data Standards
Actelion is preparing for the patent loss on its leading PAH drug not simply with a new product, but by setting a new efficacy standard across the entire PAH community.